Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination

References

1. 1.↵
   1. Tumban E.

   Lead SARS-CoV-2 candidate vaccines: expectations from phase III trials and recommendations post-vaccine approval. Viruses 2020; 13: 54.

   OpenUrl
2. 2.↵
   1. Dal-Ré R,
   2. Caplan AL,
   3. Gluud C,
   4. Porcher R.

   Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. Ann Intern Med 2021; 174: 258–260.

   OpenUrl
3. 3.↵
   Our World in Data. Coronavirus Pandemic (COVID-19). [Updated 2020; accessed 2022 Jan 1] Available from: https://ourworldindata.org/covid-vaccinations#citation
4. 4.↵
   COVID19 Vaccine Tracker. Vaccines Candidates In Clinical Trials. (Updated 2022; accessed 2021 Nov 28). Available from: https://covid19.trackvaccines.org/vaccines/
5. 5.↵
   1. Polack FP,
   2. Thomas SJ,
   3. Kitchin N,
   4. Absalon J,
   5. Gurtman A,
   6. Lockhart S, et al.

   Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383: 2603–2615.
6. 6.↵
   1. Lee EJ,
   2. Cines DB,
   3. Gernsheimer T,
   4. Kessler C,
   5. Michel M,
   6. Tarantino MD.

   Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; 96: 534–537.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Tiede A,
   2. Sachs UJ,
   3. Czwalinna A,
   4. Werwitzke S

   , BikkerR, Krauss JK. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood 2021; 138: 350–353.

   OpenUrlCrossRefPubMed
8. 8.↵
   The New York Times. Doctor’s Death After Covid Vaccine Is Being Investigated. (Updated 2021 Jan 12; accessed 2021 Nov 28). Available from: https://www.ncbi.nlm.nih.gov/search/research-news/12431/
9. 9.↵
   1. Stowe J,
   2. Kafatos G,
   3. Andrews N,
   4. Miller E.

   Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch Dis Child 2008; 93: 182–183.

   OpenUrlFREE Full Text
10. 10.↵
    1. Black C,
    2. Kaye JA,
    3. Jick H.

    MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 2003; 55: 107–111.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. France EK,
    2. Glanz J,
    3. Xu S,
    4. Hambidge S,
    5. Yamasaki K,
    6. Black SB.

    Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 121: e687–e692.
12. 12.↵
    1. Kuter DJ.

    Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol 2001; 195: 365–370.

    OpenUrl
13. 13.↵
    1. Alamer E,
    2. Hakami F,
    3. Hamdi S,
    4. Alamer A,
    5. Awaf M,
    6. Darraj H, et al.

    Knowledge, attitudes and perception toward COVID-19 vaccines among adults in Jazan province, Saudi Arabia. Vaccines (Basel) 2021; 9: 1259.

    OpenUrl
14. 14.↵
    1. Alhazmi A,
    2. Alamer E,
    3. Daws D,
    4. Hakami M,
    5. Darraj M,
    6. Abdelwahab S, et al.

    Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines (Basel) 2021; 9: 674.

    OpenUrl
15. 15.↵
    1. Nguyen TH,
    2. Medvedev N,
    3. Delcea M,
    4. Greinacher A.

    Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun 2017; 8: 14945.

    OpenUrl
16. 16.↵
    Centers for Disease Control and Prevention. HAN Archive - Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine. (Updated 2021 Apr 13; accessed 2021 Nov 28). Available from: https://emergency.cdc.gov/han/2021/han00442.asp
17. 17.↵
    1. Warkentin TE,
    2. Kelton JG.

    Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286–1292.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Sørvoll IH,
    2. Horvei KD,
    3. Ernstsen SL,
    4. Laegreid 1,
    5. Svetlana Lund IJ,
    6. Grønli RH, et al.

    An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. J Thromb Haemost 2021; 19: 1813–1818.

    OpenUrl
19. 19.↵
    1. Thiele T,
    2. Ulm L,
    3. Holtfreter S,
    4. Schönborn L,
    5. Kuhn SO,
    6. Scheer C, et al.

    Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood 2021; 138: 299–303.

    OpenUrl
20. 20.↵
    1. Sangli S,
    2. Virani A,
    3. Cheronis N,
    4. Vannatter B,
    5. Minich C,
    6. Noronha S, et al.

    Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med 2021; 174: 1480–1482.

    OpenUrl
21. 21.↵
    1. Pishko AM,
    2. Cuker A.

    Thrombosis after vaccination with messenger RNA-1273: Is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome? Ann Intern Med 2021; 74: 1468–1469.

    OpenUrl
22. 22.↵
    1. Sachs UJ,
    2. von Hesberg J,
    3. Santoso S,
    4. Bein G,
    5. Bakchoul T.

    Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost 2011; 106: 1197–1202.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Leroux D,
    2. Hezard N,
    3. Lebreton A,
    4. Bauters A,
    5. Suchon P,
    6. de Maistre E, et al.

    Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2014; 166: 774–782

    OpenUrlCrossRefPubMed